A study of Δnp63 expression in lung non-small cell carcinomas

American Journal of Surgical Pathology

Volumn 36, Issue 6, 2012, Pages 895-899

  Nonaka, Daisuke ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Np63; Adenocarcinoma; Lung; P40; P63; Squamous cell carcinoma

Indexed keywords

CKAP4 PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE PROTEIN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TTF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; ARTICLE; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MEMBRANE PROTEINS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84861231326     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182498f2b     Document Type: Article

References (22)

1. Candi E, Cipollone R, Rivetti d V, et al. p63 in epithelial development. Cell Mol Life Sci. 2008;65:3126-3133.
2. Conde E, Angulo B, Redondo P, et al. The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One. 2010;5:e12209.
3. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494-501. (Pubitemid 34193969)
4. Ivan D, Hafeez DA, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol. 2005;18:137-142. (Pubitemid 40128106)
5. Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009;37: 178-183.
6. Koga F, Kawakami S, Kumagai J, et al. Impaired delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer. 2003;88:740-747. (Pubitemid 36411454)
7. Koster MI, Lu SL, White LD, et al. Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Res. 2006;66:3981-3986.
8. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15-25.
9. Nekulova M, Holcakova J, Coates P, et al. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011;16:296-327.
10. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol. 2010;5:436-441.
11. Nonaka D, Chiriboga L. Basal cell differentiation in lung adenocarcinoma. Mod Pathol. 2008;211(suppl):348A. abstract.
12. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002; 198:417-427. (Pubitemid 35446994)
13. Pelosi G, Sonzogni A, Papotti M, et al. Different prevalence of transactivating (TA) p63 and non-TAp63 isoforms in pulmonary adenocarcinomas: a useful diagnostic tool. ModPathol. 2010; 23(1, suppl):411a-412a. abstract.
14. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132. (Pubitemid 37056135)
15. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24:1348-1359.
16. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117:3416-3423.
17. Shih IM, Kurman RJ. p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol. 2004; 28:1177-1183. (Pubitemid 39127511)
18. Travis WD, Brambilla E, Mü ller-Hermelink HK, et al. Tumours of the lung. In: Travis WD, Brambilla E, Mü ller-Hermelink HK, Harris CC, eds. Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004:9-124.
19. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
20. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol. 2011;6:1190-1199.
21. Uramoto H, Sugio K, Oyama T, et al. Expression of the p53 family in lung cancer. Anticancer Res. 2006;26:1785-1790. (Pubitemid 43989432)
22. Yao JY, Pao CC, Chen JK. Transcriptional activity of TAp63 promoter is regulated by c-jun. J Cell Physiol. 2010;225:898-904.